December 25, 2023
Japan’s health ministry on December 22 granted orphan drug designation to five drugs including an additional indication for MSD’s Keytruda (pembrolizumab) and Amgen’s teprotumumab, known as Tepezza overseas. Keytruda obtained the orphan status for an indication of concurrent chemoradiotherapy in...read more